We have used the SerpinB3 and PAR2 inhibitor 1-PPA [[28], [29], [30]] to explore its ability to reduce the development of NASH in two different mouse models. This evidence concerns the gene F2RL1 and metabolic dysfunction-associated steatohepatitis.